LTKfarma

LTKfarma is a French biotechnology company specializing in the development of next-generation cell and gene therapies for oncology. The company's proprietary LentiKine platform enables the engineering of immune cells, such as T cells and NK cells, to express membrane-bound cytokines like IL-2 and IL-15. This localized expression provides essential survival and activation signals directly to the therapeutic cells, allowing them to function autonomously within the immunosuppressive microenvironment of solid tumors. By avoiding systemic cytokine administration, LTKfarma's approach aims to enhance anti-tumor efficacy while minimizing the severe toxicities often associated with immunotherapy.